About US
Contact us
-
Pfizer acquires Baxter's marketed vaccines portfolio for $635mUS-based drug maker Pfizer has completed the acquisition of marketed vaccines portfolio from Baxter International for $635m. As part of the deal, Pfizer also acquired a portion of Baxter's facility i2014/12/3
-
UK Medical Research Council scientists create world's first synthetic enzymesScientists at the UK's Medical Research Council (MRC) have created the world's first enzymes made from artificial genetic material, which are capable of triggering chemical reactions in the laboratory2014/12/3
-
Daiichi and UCB Biopharma partner to introduce epilepsy treatment Lacosamide in JapanJapan-based Daiichi Sankyo has signed an agreement with UCB Biopharma to jointly commercialise Lacosamide for the treatment of patients with epilepsy in Japan.As part of the deal, UCB will manufacture2014/12/2
-
AstraZeneca and Cancer Research UK collaborate for new cancer medicines screeningBritish-Swedish drugmaker AstraZeneca has signed a memorandum of understanding (MoU) to provide drug discovery facilities for Cancer Research UK at its new MRC UK Centre for Lead Discovery in Cambridg2014/12/2
-
Global Vision Expands Reseller Agreement with Crest Solutions for the UK and IrelandGlobal Vision has announced its appointment of Crest Solutions as its representative in the UK, expanding the territory of Crest Solutions to the UK and Ireland. The arrangement builds on an existing2014/12/2
-
Hovione submits first IND Application with FDA for minocycline gelHovione announced today it has filed its first Investigational New Drug (IND) Application with the U.S. Food and Drug Administration (FDA). This event represents a milestone in Hovione's strategy of d2014/12/1
-
NICE recommends Nalmefene to reduce alcohol consumptionThe UK's National Institute for Health and Care Excellence (NICE) has recommended the use of Nalmefene to reduce the urge to consume alcohol. The new drug has been licensed for use, alongside psychos2014/12/1
-
Nordic Nanovector and Affibody to develop new RIT for multiple myelomaNordic Nanovector has signed a three-year collaborative research agreement with Affibody to develop new advanced radio-immunotherapies (RIT) for multiple myeloma. Supported by a grant from Eurostars,2014/12/1
-
Challenges for Innovators in the US Pharmaceutical MarketProfitable and continuous participation in the US pharmaceutical market is fraught with challenges. The barriers to entry are considerable and sustained growth is always in question. Innovators oper2014/11/28
-
Japan grants orphan drug designation for Alexion’s Soliris to treat NMOUS-based Alexion Pharmaceuticals has obtained orphan drug designation (ODD) from Japan's Ministry of Health, Labour and Welfare (MHLW) for its Soliris (eculizumab) for the treatment of neuromyelitis o2014/11/28